ivonescimab
ivonescimab: developed by 1 company · 35 clinical trials tracked.
ivonescimab evidence translation
What we can confirm
35 tracked trials
What it means
What to watch
Prepared research question
How could ivonescimab → SMMT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 2 study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Summit Therapeutics Inc. (SMMT) | Phase 3 |
Clinical Trials (35)showing 10 most recent
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Primary endpoint: Safety and adverse events (AEs)
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Primary endpoint: Safety and adverse events (AEs).
A Phase II/III Randomized Study of Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer
Primary endpoint: Overall survival (OS)
A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC
Primary endpoint: Intracranial progression-free survival based on local assessment using RANO-BM criteria
A Phase II Study of Neoadjuvant Ivonescimab in Patients With High-Risk, Localized RCC
Primary endpoint: Proportion of patients achieving a best overall response (ORR)
Randomized Phase 2 Study of Second-line Chemotherapy Comparing FOLFIRI + Ivonescimab Versus FOLFIRI + Bevacizumab in Microsatellite Stable (MSS)/ Proficient MisMatch Repair (pMMR) BRAF Wild Type (BRAFwt) Advanced Colorectal Cancer (mCRC) Without Liver Metastases
Primary endpoint: Progression Free Survival (PFS)
A Prospective, Parallel, Double-cohort, Multicenter Phase II Clinical Study of Ivonescimab (AK112) Combined With IP Chemotherapy ± TACE for First-line Treatment of Metastatic Digestive System Neuroendocrine Cancer
Primary endpoint: progression-free survival (PFS)
A Phase I Clinical Trial of Ivonescimab and ADG126, Alone, and in Combination With 5-FU/LV or FOLFIRI in MSS Advanced/Metastatic Colorectal Cancer
Primary endpoint: Incidence of dose limiting toxicities
A Pilot Study of Tepotinib + Ivonescimab in Patients With Advanced METex14 Skipping Positive NSCLC
Primary endpoint: Dose finding
A Randomized, Open-label, Multicenter, Phase 3 Trial of Ivonescimab Alone or With Ligufalimab Versus Pembrolizumab in First-line Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary endpoint: Overall survival
Frequently asked questions
Who is developing ivonescimab?
ivonescimab is being developed by Summit Therapeutics Inc..
How many clinical trials involve ivonescimab?
BioSniper tracks 35 clinical trials involving ivonescimab.